Physicians' ability to predict the risk of coronary heart disease

BMC Health Services Research

Volumn 3, Issue , 2003, Pages 1-6

  Pignone, Michael ^a   Phillips, Christopher J ^b   Elasy, Tom A ^c   Fernandez, Alicia ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b USAF   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACCURACY; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL LIVER LEVEL; FEMALE; HEALTH SURVEY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PHARMACEUTICAL CARE; PHYSICIAN; PREDICTION; QUESTIONNAIRE; RESIDENT; RISK REDUCTION; SUDDEN DEATH; THERAPEUTIC ERROR; UNIVERSITY HOSPITAL;

EID: 2942543944     PISSN: 14726963     EISSN: None     Source Type: Journal    
DOI: 10.1186/1472-6963-3-1     Document Type: Article

References (19)

1. Hoyert DL, Kochanek KD and Murphy SL: Deaths: final data for 1997 Natl Vital Stat Rep 1999, 47:1-104.
2. American Heart Association: 2002 Heart and Stroke Statistical Update. 30.
3. The health benefits of smoking cessation: a report of the Surgeon General Rockville, US Department of Health and Human Services, Public Health Service, and Centers for Disease Control.
4. Pignone M and Mulrow CD: Evidence based management of hypertension: Using cardiovascular risk profiles to individualise hypertensive treatment BMJ 2001, 322:1164-6.
5. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD and Lohr KN: Screening and treating adults for lipid disorders Am J Prev Med 2001, 20:77-89.
6. Hayden M, Pignone M, Phillips C and Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the u.s. Preventive services task force Ann Intern Med 2002, 136:161-72.
7. Pignone M, Phillips C and Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials BMJ 2000, 321:983-6.
8. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L and Abrahamowicz M: Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study BMJ 1995, 310:975-8.
9. Friedmann PD, Brett AS and Mayo-Smith MF: Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease Ann Intern Med 1996, 124:414-21.
10. Chatellier G, Blinowska A, Menard J and Degoulet P: Do physicians estimate reliably the cardiovascular risk of hypertensive patients? Medinfo 1995, 8 Pt 2:876-9.
11. McManus RJ, Mant J, Meulendijks CF, Salter RA, Pattison HM and Roalfe AK et al.: Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study BMJ 2002, 324:459-64.
12. Montgomery AA, Fahey T, MacKintosh C, Sharp DJ and Peters TJ: Estimation of cardiovascular risk in hypertensive patients in primary care Br J Gen Pract 2000, 50:127-8.
13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H and Kannel WB: Prediction of coronary heart disease using risk factor categories Circulation 1998, 97:1837-47.
14. Peabody JW, Luck J, Glassman P, Dresselhaus TR and Lee M: Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality JAMA 2000, 283:1715-22.
15. Dresselhaus TR, Peabody JW, Lee M, Wang MM and Luck: Measuring compliance with preventive care guidelines: standardized patients, clinical vignettes, and the medical record J Gen Intern Med 2000, 15:782-8.
16. Redelmeier DA, Ferris LE, Tu JV, Hux JE and Schull MJ: Problems for clinical judgement: introducing cognitive psychology as one more basic science CMAJ 2001, 164:358-60.
17. Jackson PR, Wallis EJ, Haq IU and Ramsay LE: Statins for primary prevention: at what coronary risk is safety assured? Br J Clin Pharmacol 2001, 52:439-46.
18. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU and Yeo WW et al.: Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Heart 1999, 82:325-32.
19. Grundy SM: Primary prevention of coronary heart disease: integrating risk assessment with intervention Circulation 1999, 100:988-98.